Refractory Lymphomas Recruiting Phase 2 Trials for DB00072 (Trastuzumab)

Also known as: Refractory Lymphoma

Indication	Status	Phase
DBCOND0042145 (Refractory Lymphomas)	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Treatment	DB12218 (AZD-5363) DB08916 (Afatinib) DB11967 (Binimetinib) DB08865 (Crizotinib) DB08912 (Dabrafenib) DB01254 (Dasatinib) DB12282 (Defactinib) DB11795 (GSK-2636771) DB11740 (MK-1775) DB09035 (Nivolumab) DB09330 (Osimertinib) DB09073 (Palbociclib) DB06366 (Pertuzumab) DB11836 (Sapanisertib) DB01268 (Sunitinib) DB12108 (Taselisib) DB08911 (Trametinib) DB00072 (Trastuzumab) DB05773 (Trastuzumab emtansine) DB08828 (Vismodegib)